Triple Negative Breast Cancer and Celecoxib. Pilot Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Relapses occur in 20 to 30% of patients with early-stage triple-negative breast cancer (TNBC), which is characterized by the absence of three receptors: the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). Radiotherapy (RT) can increase or decrease, depending on the patient, the level of cytokines that promote metastasis development. To help prevent the development of metastasis, the cyclooxygenase-2 (COX-2) inhibitor celecoxib will be administered during RT. This treatment aims to prevent RT-induced cytokine increases and, ultimately, improve patient prognosis. The primary objective of this pilot study is to assess the feasibility of recruiting participants and implementing the study steps, with the intention of conducting a large-scale study in the future. The secondary objective is to evaluate celecoxib ability to inhibit the RT-induced stimulation of cytokines associated with metastasis development. This will be assessed by comparing the levels of these cytokines in plasma samples collected before, during, and after RT. In the exploratory objective, TNBC cells will be incubated in vitro with these plasma samples to determine whether administering celecoxib during RT can prevent increased cancer cell invasion and metastasis formation in mice.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta
- •Wiek 18 lat lub więcej
- •Wczesne stadium raka piersi
- •Rak piersi potrójnie ujemny (potwierdzony badaniem)
- •Brak przerzutów do odległych narządów
- •Guz piersi usunięty operacyjnie z czystymi marginesami
✗ Disqualifies
- •Choroba wrzodowa żołądka w ciągu ostatnich 6 miesięcy
- •Choroby nerek (znacznie obniżona zdolność filtrowania)
- •Choroby wątroby (znacznie podwyższone enzymy wątrobowe, bilirubina lub inne problemy)
- •Niewydolność serca (znacznie obniżona zdolność pompowania krwi)
- •Przyjmowanie leków przeciwzapalnych (NLPZ) z innego powodu w ciągu ostatnich 6 miesięcy
- •Nadwrażliwość na celekoxib lub sulfonamidy
- •Astma, pokrzywka lub reakcje alergiczne po aspirynie lub innych lekach przeciwzapalnych
- •Choroby zapalne jelit
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Faculty of medicine and health sciences
Sherbrooke, Canada
Trial contact
Benoit Paquette, Ph.D.
Hélène Therriault, M.Sc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.